RecruitingPhase 1Phase 2NCT06730750

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Sponsor

Bristol-Myers Squibb

Enrollment

360 participants

Start Date

Feb 12, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called BMS-986490, alone or combined with bevacizumab (a drug that cuts off blood supply to tumors), in people with advanced solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and gastric (stomach) cancer. **You may be eligible if...** - You have been diagnosed with advanced, unresectable or metastatic colorectal cancer, non-small cell lung cancer, or gastric cancer - Your cancer has progressed after standard treatments (such as chemotherapy or immunotherapy) - Your tumor is measurable on imaging - You are in adequately good health to tolerate the treatment **You may NOT be eligible if...** - You have not previously received standard treatments appropriate for your cancer type - You have major organ dysfunction or other serious health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.